MGF is a splice variant of IGF-1 produced in muscle tissue that activates satellite cells to promote hypertrophy and repair; off-label, people run it for muscle growth and recovery, though the entire captured community corpus is only five reports and outcomes are split. Community posts rarely specify dosing, while clinician sources cite 200 mcg by intramuscular injection, though timing and cycling remain largely unspecified. It carries no FDA-approved indication for human use, so all human use is off-label or compounded.

Research Evidence
Evidence shape
MGF sits at the animal-only tier: exactly one indication is mapped, entirely to preclinical mechanistic research, and zero trials are registered. No trials have been completed, leaving no posted results to evaluate. Beyond that single animal-only area, the dataset holds no thin indications and no populated clinical programs; the total absence of clinical data is the signal.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How MGF is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Clinician protocols dose 200 µg weekly IM (2 sources).
Community reports mention MGF use for muscle growth, recovery, and injury healing. Doses, frequencies, and routes are not consistently reported across these anecdotal accounts.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for MGF, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.